Migraine patchmaker NuPathe chooses buyer Teva over Endo; Alnylam enters PhI with hemophilia RNAi drug;

> NuPathe, the maker of the Zecuity transdermal patch for migraine treatment, decided not to accept Endo Health Solutions' ($ENDP) offer of about $105 million and opted instead for Teva Pharmaceutical Industries' ($TEVA) offer of about $114 milliion. More

> Alnylam ($ALNY) entered the clinic with its RNAi candidate ALN-AT3. The Phase I trial will focus on the treatment of hemophilia and rare bleeding disorders. Release

> New Jersey-based Alitair Pharmaceuticals won a U.S. patent for its ion exchange resin drug delivery technology. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.